A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/13/2006	EP1730163A1 Pharmaceuticals salts of 3-o-(3,3-dimethylsuccinyl) betulinic acid
12/13/2006	EP1730159A1 Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same
12/13/2006	EP1730155A1 Thienopyrroles as antagonists of gnrh
12/13/2006	EP1730154A2 Rifamycin derivatives effective against drug-resistant microbes
12/13/2006	EP1730152A2 Tetrahydroquinoline derivatives and a process for preparing the same
12/13/2006	EP1730151A1 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
12/13/2006	EP1730148A2 Aminobenzoxazoles as therapeutic agents
12/13/2006	EP1730147A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-on compounds for use in the treatment of obesity
12/13/2006	EP1730145A1 Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
12/13/2006	EP1730144A1 Substituted 1,4,8-triazaspiro¬4.5\|decan-2-one compounds
12/13/2006	EP1730142A1 Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
12/13/2006	EP1730141A1 Compounds for the treatment of diseases
12/13/2006	EP1730140A1 Opioid receptor antagonists
12/13/2006	EP1730139A2 Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
12/13/2006	EP1730138A1 Epothilone derivatives
12/13/2006	EP1730137A1 Heterocyclic cgrp antagonists for the treatment of migraine
12/13/2006	EP1730136A1 N-piperidine derivates as ccr3 modulators
12/13/2006	EP1730135A1 Qiunolin-4-ones as inhibitors of retroviral integrase for the treatment of hiv, aids and aids related complex (arc)
12/13/2006	EP1730134A1 Pyridine inhibitors of erk2 and uses thereof
12/13/2006	EP1730133A1 Benzothiophene- and thiochromene containing phenethanolamine derivatives for the treatment of respiratory disorders
12/13/2006	EP1730131A1 Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
12/13/2006	EP1730130A1 Beta-ketoamide compounds having an mch-antagonistic effect and medicaments containing said compounds
12/13/2006	EP1730127A1 Heterocyclic phenylaminopropanol derivatives as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms)
12/13/2006	EP1730126A1 Novel benzoxazinone derivatives used as long-acting betamimetics for treating respiratory illnesses
12/13/2006	EP1730125A2 Substituted hydroxyethylamine aspartyl protease inhibitors
12/13/2006	EP1730124A1 Certain triazole-based compounds, compositions, and uses thereof
12/13/2006	EP1730122A2 Pyrimidine derivatives and methods of treatment related to the use thereof
12/13/2006	EP1730121A2 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
12/13/2006	EP1730120A1 Non-nucleoside reverse transcriptase inhibitors
12/13/2006	EP1730119A1 Imidazole compounds for the treatment of neurodegenerative disorders
12/13/2006	EP1730118A1 Substituted azole derivatives, compositions, and methods of use
12/13/2006	EP1730116A1 4-carbox pyrazole derivates useful as anti-viral agents
12/13/2006	EP1730115A1 5-aminoalkylpyrazole derivatives as pesticidal agents
12/13/2006	EP1730113A1 Process for the synthesis of a cxcr4 antagonist
12/13/2006	EP1730112A1 3-((hetero)arylsulfonyl)-8'[ (aminoalkyl)oxy]quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders
12/13/2006	EP1730111A2 Substituted bisarylurea derivatives as kinase inhibitors
12/13/2006	EP1730110A1 Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
12/13/2006	EP1730104A1 Chemical process and new crystalline form
12/13/2006	EP1730103A1 Formamide derivatives useful as adrenoceptor
12/13/2006	EP1730099A2 Mitotic kinesin inhibitors
12/13/2006	EP1730098A2 Method of exchanging anions of tetraalkylammonium salts
12/13/2006	EP1730095A2 Novel cyclopentenedione antifungal compounds and methods for their use
12/13/2006	EP1729851A2 Compositions comprising reverse isomers of conjugated linoleic acid
12/13/2006	EP1729820A2 Perturbed membrane-binding compounds and methods of using the same
12/13/2006	EP1729819A1 X-ray visible drug delivery device
12/13/2006	EP1729812A1 Stable pharmaceutical composition comprising an ace inhibitor
12/13/2006	EP1729811A1 Cream-gel containing ivermectin
12/13/2006	EP1729810A2 Methods of reducing aggregation of il-1ra
12/13/2006	EP1729809A2 Dietary supplement and method for treating digestive system-related disorders
12/13/2006	EP1729808A2 Combination therapy with azd2171 and 5-fu and/or cpt-11
12/13/2006	EP1729807A2 Combination therapy
12/13/2006	EP1729797A1 Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
12/13/2006	EP1729786A2 Administration of cisplatin by inhalation
12/13/2006	EP1729784A1 Formulations of thiomolybdate or thiotungstate compounds and uses thereof
12/13/2006	EP1729783A1 Biodegradable polyurethane and polyurethane ureas
12/13/2006	EP1729782A2 Treatment and prophylaxis of sepsis and septic shock
12/13/2006	EP1729781A1 A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
12/13/2006	EP1729780A2 Methods for protein production
12/13/2006	EP1729779A2 Coating method
12/13/2006	EP1729778A2 Pharmaceutical preparation containing drospirenone for application to the skin
12/13/2006	EP1729777A1 Pharmaceutical composition comprising a salt of mirtazapine
12/13/2006	EP1729776A1 Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists
12/13/2006	EP1729775A2 Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin
12/13/2006	EP1729774A1 Pyrrolidine compounds
12/13/2006	EP1729773A1 8-hydroxy-5- [(-hydroxy-2- [[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation
12/13/2006	EP1729772A2 Heteroaryl piperidine glycine transporter inhibitors
12/13/2006	EP1729771A1 Pyridyl derivatives and their use as mglu5 receptor antagonists
12/13/2006	EP1729770A1 Sns-595 and methods of using the same
12/13/2006	EP1729769A1 Compositions with reduced hepatotoxicity
12/13/2006	EP1729768A2 Immune response modifier formulations and methods
12/13/2006	EP1729767A1 Combination of a heterocyclic compound and an antioxidant and use thereof for treating obesity
12/13/2006	EP1729766A1 Pharmaceutical formulation
12/13/2006	EP1729765A1 Use of a pyrazole derivative for producing medicaments that are useful in preventing and treating chronic bronchitis and chronic obstructive bronchopneumopathy
12/13/2006	EP1729764A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
12/13/2006	EP1729763A2 Novel bicyclic compounds as modulators of androgen receptor function and method
12/13/2006	EP1729762A2 Combination therapy for weight management
12/13/2006	EP1729761A1 Cadasil treatment with cholinesterase inhibitors
12/13/2006	EP1729760A2 Use of beta-lapachone for the treatment of lung cancer
12/13/2006	EP1729759A1 Salvinorin derivatives and uses thereof
12/13/2006	EP1729758A1 Andrographolide and analogues as inhibitors of tnf alpha and il-1 beta expression
12/13/2006	EP1729757A2 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
12/13/2006	EP1729756A2 Novel pharmaceutical compositions
12/13/2006	EP1729755A1 Methods of treatment of amyloidosis using aspartyl-protease inihibitors
12/13/2006	EP1729754A2 Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
12/13/2006	EP1729753A2 Use of an nmda receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity
12/13/2006	EP1729752A2 Method for treating aortic stenosis with non-antibacterial tetracycline formulations
12/13/2006	EP1729751A1 Use of an nk3 antagonist for the treatment of bipolar disorders
12/13/2006	EP1729750A2 Method for inhibiting tumor formation and growth
12/13/2006	EP1729749A2 Use of renin inhibitors in therapy
12/13/2006	EP1729748A1 Microemulsion preconcentrate comprising a renin inhibitor
12/13/2006	EP1729747A2 Thiol reactive agents as a therapeutic modality
12/13/2006	EP1729746A2 Means for transdermal administration of nicotine
12/13/2006	EP1729743A1 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
12/13/2006	EP1729740A2 PHARMACEUTICAL DOSAGE FORMS HAVING IMMEDIATE RELEASE AND/OR CONTROLLED RELEASE PROPERTIES THAT CONTAIN A GABA<SB>B</SB> RECEPTOR AGONIST
12/13/2006	EP1729739A1 Process for preparing a solid pharmaceutical composition
12/13/2006	EP1729737A1 Disintegrating tablets comprising licarbazepine
12/13/2006	EP1729736A2 Galenic formulations of organic compounds
12/13/2006	EP1729734A2 Spray dried pharmaceutical compositions
12/13/2006	EP1729732A1 Anionic hyrdogel matrices with ph dependent modified release as drug carriers
12/13/2006	EP1729728A1 Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient

1 ... 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 3979 3980 3981 3982 3983 3984 3985 3986 3987 3988 3989 ... 7860